title: IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
abstract: Mucopolysaccharidosis type II (MPSII), or Hunter syndrome, arises from a deficiency in iduronate 2-sulfatase (IDS), and it is characterized by progressive somatic and neurological involvement. The MPSII mouse model reproduces the features of MPSII patients. Systemic administration of the AAV2/5CMV-hIDS vector in MPSII mouse pups results in the full correction of glycosaminoglycan (GAG) accumulation in visceral organs and in the rescue of the defects and GAG accumulation in the central nervous system (CNS). Remarkably, in treated MPSII animals, this CNS correction arises from the crossing of the blood-brain barrier by the IDS enzyme itself, not from the brain transduction. Thus, we show here that early treatment of MPSII mice with one systemic injection of AAV2/5CMV-hIDS results in prolonged and high levels of circulating IDS that can efficiently and simultaneously rescue both visceral and CNS defects for up to 18 months after therapy.
authors.affiliation: Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
authors.forename: Vinicia Assunta
authors.initials: VA
authors.lastname: Polito
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Cosma
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001921:Brain / Q000166:cytology / Q000378:metabolism; D002490:Central Nervous System / Q000378:metabolism*; D000229:Dependovirus / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007066:Iduronate Sulfatase / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D007275:Injections, Intravenous; D008099:Liver / Q000166:cytology / Q000378:metabolism; D008168:Lung / Q000166:cytology / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D016532:Mucopolysaccharidosis II / Q000378:metabolism*; D016019:Survival Analysis
chemical_list: D006025:Glycosaminoglycans; D007066:Iduronate Sulfatase
references.citation: Pharmacol Rev. 2005 Jun;57(2):173-85
references.pmid: 15914466
references.citation: Nat Biotechnol. 2009 Jan;27(1):59-65
references.pmid: 19098898
references.citation: Cell. 2003 May 16;113(4):445-56
references.pmid: 12757706
references.citation: J Virol. 2001 Jul;75(13):6199-203
references.pmid: 11390622
references.citation: Mol Ther. 2004 Sep;10(3):478-91
references.pmid: 15336648
references.citation: J Clin Invest. 2002 Aug;110(4):499-504
references.pmid: 12189244
references.citation: Cell. 2003 May 16;113(4):435-44
references.pmid: 12757705
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2616-21
references.pmid: 18268347
references.citation: Acta Paediatr Suppl. 2002;91(439):98-9
references.pmid: 12572850
references.citation: Mol Ther. 2009 Apr;17(4):600-6
references.pmid: 19174759
references.citation: Hum Mutat. 1993;2(6):435-42
references.pmid: 8111411
references.citation: Acta Neuropathol. 2007 Nov;114(5):481-9
references.pmid: 17653558
references.citation: Hum Mol Genet. 2004 Sep 15;13(18):1979-88
references.pmid: 15269179
references.citation: Hum Mol Genet. 2006 Apr 1;15(7):1225-36
references.pmid: 16505002
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14777-82
references.pmid: 16162667